QHSLab Revenue Jumps 30%, But Losses Widen Amid Soaring Costs

Ticker: USAQ · Form: 10-Q · Filed: Aug 14, 2025 · CIK: 856984

Sentiment: bearish

Topics: Healthcare Technology, SaaS, Going Concern, Net Loss, Revenue Growth, Operating Expenses, Small Cap

Related Tickers: USAQ

TL;DR

USAQ is burning cash faster than it's growing, making it a risky bet despite revenue gains.

AI Summary

QHSLab, Inc. reported a significant increase in revenue for the three and six months ended June 30, 2025. Revenue for the three-month period rose to $605,446 from $473,073 in the prior year, a 28% increase. For the six-month period, revenue increased by 30% to $1,250,865 from $961,660. Despite this revenue growth, the company's net loss widened considerably, reaching $52,958 for the three months ended June 30, 2025, compared to a net loss of $2,890 in the same period last year. The six-month net loss also expanded to $132,567 from $21,415. This deterioration in net income is primarily due to a substantial increase in operating expenses, with general and administrative expenses rising to $254,173 for the six months from $137,397, and research and development costs nearly doubling to $236,397 from $107,450. Interest expense also more than doubled to $132,054 for the six-month period. The company continues to operate with a significant accumulated deficit of $4,463,917 as of June 30, 2025, and its 'going concern' status remains in doubt due to consistent losses and high leverage.

Why It Matters

QHSLab's substantial revenue growth, particularly in its SaaS and medical device segments, indicates strong market demand for its value-based healthcare solutions, which could attract investors looking for growth in digital health. However, the escalating net losses and 'going concern' warning signal significant operational inefficiencies and financial instability, posing a high risk for investors. Employees might face uncertainty given the company's financial health, while customers could benefit from the expanding product offerings but should monitor the company's long-term viability. In a competitive healthcare technology landscape, QHSLab's ability to convert revenue growth into profitability will be crucial for its survival and market positioning.

Risk Assessment

Risk Level: high — The company explicitly states a 'going concern' doubt due to incurred losses, high leverage, and inconsistent cash generation from operations. The accumulated deficit reached $4,463,917 as of June 30, 2025, and the net loss for the six months ended June 30, 2025, was $132,567, significantly higher than the $21,415 loss in the prior year, indicating worsening financial performance.

Analyst Insight

Investors should exercise extreme caution and consider avoiding USAQ shares until the company demonstrates a clear path to profitability and resolves its 'going concern' issues. Monitor future filings for evidence of expense control, improved cash flow from operations, and successful equity or debt financing to stabilize its financial position.

Financial Highlights

debt To Equity
N/A
revenue
$1,250,865
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
-$132,567
eps
N/A
gross Margin
N/A
cash Position
$168,400
revenue Growth
+30%

Key Numbers

Key Players & Entities

FAQ

What were QHSLab, Inc.'s revenues for the three and six months ended June 30, 2025?

QHSLab, Inc.'s revenue for the three months ended June 30, 2025, was $605,446, an increase from $473,073 in the prior year. For the six months ended June 30, 2025, revenue was $1,250,865, up from $961,660 in the same period of 2024.

Did QHSLab, Inc. achieve profitability in the latest quarter?

No, QHSLab, Inc. did not achieve profitability. The company reported a net loss of $52,958 for the three months ended June 30, 2025, and a net loss of $132,567 for the six months ended June 30, 2025.

What is the primary reason for QHSLab, Inc.'s increased net loss?

The primary reason for QHSLab, Inc.'s increased net loss is a significant rise in operating expenses and interest expense. General and administrative expenses increased to $254,173 for the six months ended June 30, 2025, from $137,397, and research and development expenses nearly doubled to $236,397 from $107,450. Interest expense also more than doubled to $132,054.

What is QHSLab, Inc.'s current cash position?

As of June 30, 2025, QHSLab, Inc. had cash and cash equivalents of $168,358. This is a slight increase from $157,168 at December 31, 2024, but remains a low amount for ongoing operations.

What is the 'going concern' warning for QHSLab, Inc.?

QHSLab, Inc. has incurred losses during most fiscal quarters since inception, is highly leveraged, and does not consistently generate cash from operations. These conditions raise substantial doubt about the company's ability to continue as a going concern, as stated in Note 2 of the financial statements.

How much common stock did QHSLab, Inc. have outstanding as of August 14, 2025?

As of August 14, 2025, QHSLab, Inc. had 11,281,527 shares of common stock outstanding. This is an increase from 10,806,527 shares outstanding at December 31, 2024.

What types of services does QHSLab, Inc. provide?

QHSLab, Inc. is a medical device technology and software-as-a-service (SaaS) company. It focuses on enabling primary care physicians to increase revenues by providing value-based tools for evaluating and treating chronic disease, preventive care, allergy diagnostic-related products, immunotherapy treatments, and digital medicine services.

What are QHSLab, Inc.'s total liabilities as of June 30, 2025?

As of June 30, 2025, QHSLab, Inc.'s total liabilities were $2,354,356. This includes accounts payable of $362,162, other current liabilities of $411,087, loans payable of $371,960, and convertible notes payable of $1,209,147.

How has QHSLab, Inc.'s research and development spending changed?

QHSLab, Inc.'s research and development spending significantly increased. For the six months ended June 30, 2025, R&D expenses were $236,397, nearly doubling from $107,450 in the same period of 2024.

What is QHSLab, Inc.'s strategy for addressing its 'going concern' issues?

The continuation of QHSLab, Inc.'s business is dependent upon its ability to achieve increased positive cash flows and continual profitability. Pending such achievements, the company relies on future issuances of equity or other financings to fund ongoing operations, though access to such funding may not be available on commercially reasonable terms.

Risk Factors

Industry Context

QHSLab, Inc. operates in a sector likely characterized by rapid technological advancement and significant R&D investment. Companies in this space often face intense competition, requiring continuous innovation to maintain market share. Funding for early-stage or growth-stage companies can be challenging, especially when profitability is not yet achieved.

Regulatory Implications

As a publicly traded company, QHSLab, Inc. must adhere to SEC reporting requirements, including timely filing of 10-Q and 10-K reports. Failure to maintain adequate financial controls or address 'going concern' issues could lead to increased scrutiny from regulators and investors.

What Investors Should Do

  1. Monitor expense management closely: Investors should scrutinize the drivers of increased operating expenses (G&A, R&D) and interest costs to assess if they are sustainable or indicative of deeper financial issues.
  2. Evaluate path to profitability: Given the widening net loss despite revenue growth, investors need to understand the company's strategy and timeline for achieving profitability.
  3. Assess liquidity and funding needs: The low cash position and high current liabilities suggest potential future financing needs. Investors should monitor any announcements regarding capital raises or debt restructuring.

Glossary

Accumulated Deficit
The cumulative net losses of a company that have not been offset by net income or other gains since its inception. (Indicates the company's history of unprofitability and its current financial strain, impacting its going concern status.)
Going Concern
An assumption that a company will continue to operate for the foreseeable future, typically at least 12 months from the reporting date. (The company's financial condition raises doubts about its ability to continue as a going concern, requiring disclosure and potential mitigation strategies.)

Year-Over-Year Comparison

Compared to the prior year, QHSLab, Inc. has demonstrated strong revenue growth, with a 28% increase in Q2 and 30% for the six months. However, this top-line improvement has been overshadowed by a significant widening of the net loss, driven by substantial increases in operating and interest expenses. The accumulated deficit remains a concern, and the company's financial health appears more precarious despite revenue gains.

Filing Stats: 4,429 words · 18 min read · ~15 pages · Grade level 15.7 · Accepted 2025-08-14 08:30:50

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION ITEM 1.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS. 4 ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. 18 ITEM 4.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES. 22

- OTHER INFORMATION

PART II - OTHER INFORMATION ITEM 6. EXHIBITS. 23 2 Cautionary Note Regarding Forward-Looking Statements This report contains forward-looking statements. Certain of the matters discussed herein concerning, among other items, our operations, cash flows, financial position and economic performance including, in particular, future sales, product demand, competition and the effect of economic conditions, include forward-looking statements. Forward-looking "anticipates," "intends," "plans," "believes," "estimates" and similar expressions. Although we believe that the forward-looking statements contained in this report are based upon reasonable assumptions, these statements and other projections contained herein expressing opinions about future outcomes and non-historical information, are subject to uncertainties and, therefore, there is no assurance that the outcomes expressed in these statements will be achieved. Investors are cautioned that forward-looking statements are not guarantees of future performance and actual results or developments may differ materially from the expectations expressed in forward-looking statements contained herein. Given these uncertainties, you should not place any reliance on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. You are advised, however, to consult any additional disclosures we make in our reports filed with the Securities and Exchange Commission ("SEC"). 3 PART I – FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS (unaudited) Condensed Consolidated Balance Sheets – June 30, 2025 (unaudited) and December 31, 2024 5 Condensed Consolidated S

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing